November 18th, 2013
Selections from Richard Lehman’s Literature Review: November 18th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the VA-NEPHRON-D and IABP-SHOCK II trials, a study of the sex differences in ACS symptoms among young patients, and more.
August 30th, 2011
No Benefit for Routine Counterpulsation Found in CRISP AMI
Larry Husten, PHD
Routine use of intra-aortic balloon counterpulsation (IABC) in STEMI patients who do not have cardiogenic shock does not reduce infarct size, according to a new trial. Results from the CRISP AMI (Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction) trial were presented at the European Society of Cardiology meeting in Paris by Manesh Patel […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?